-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On October 25, CDE official website showed that Hengrui Medicine's SHR-A1921 clinical trial application was approved by the China Food and Drug Administration
SHR-A1921 is an antibody-conjugated drug (ADC) for the treatment of advanced malignant solid tumors
In recent years, Hengrui has also continued to deploy ADC drugs
Among the 7 Hengrui drugs that entered the clinic, 3 drugs were approved for the first time in 2021, namely SHR-A1912, SHR-A2009, and SHR-A1921